[go: up one dir, main page]

Jump to content

Ro48-8684: Difference between revisions

Page 1
Page 2
Content deleted Content added
CheMoBot (talk | contribs)
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wik
CAS from https://synapse.patsnap.com/drug/8792804560a54d75872c5c6c350a4fac
 
(14 intermediate revisions by 14 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 450848725
| verifiedrevid = 451550070
| IUPAC_name = 3-(5-dipropylaminomethyloxazol-2-yl)-8-fluoro-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
| IUPAC_name = 3-(5-dipropylaminomethyloxazol-2-yl)-8-fluoro-5-methyl-5,6-dihydro-4''H''-imidazo[1,5-''a''][1,4]benzodiazepin-6-one
| image = Ro48-8684_structure.png
| width = 200
| image = Ro48-8684.svg
| width = 242


<!--Clinical data-->
<!--Clinical data-->
| tradename =
| tradename =
| legal_status =
| legal_status =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
Line 13: Line 15:
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number = 179634-04-9
| PubChem = 9866317
| PubChem = 9866317
| ChemSpiderID = 8042008
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}


<!--Chemical data-->
<!--Chemical data-->
| C=22 | H=26 | F=1 | N=5 | O=2
| C=22 | H=26 | F=1 | N=5 | O=2
| smiles = CCCN(CC1=CN=C(C2=C(CN(C(C3=C4C=CC(F)=C3)=O)C)N4C=N2)O1)CCC
| molecular_weight = 411.472
| StdInChI = 1S/C22H26FN5O2/c1-4-8-27(9-5-2)12-16-11-24-21(30-16)20-19-13-26(3)22(29)17-10-15(23)6-7-18(17)28(19)14-25-20/h6-7,10-11,14H,4-5,8-9,12-13H2,1-3H3
| smiles = CCCN(CCC)Cc(cn3)oc3-c2ncn-1c2CN(C)C(=O)c4cc(F)ccc-14
| StdInChIKey = YKKLHEHNUYCLQQ-UHFFFAOYSA-N
}}
}}


'''Ro48-8684''' is a water-soluble [[benzodiazepine]] derivative developed by [[Hoffman-LaRoche]] in the 1990s, which was designed along with [[Ro48-6791]] as an improved replacement for [[midazolam]], but ultimately proved to have little advantages over the parent drug and has not been introduced into clinical practice.<ref>van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, Heizmann P, Zell M, Cohen AF, Dingemanse J. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ''British Journal of Clinical Pharmacology''. 1997 Nov;44(5):487-93. PMID 9384466</ref><ref>Albrecht S, Hering W, Ihmsen H, Schwilden H, Schüttler J. Pharmacokinetic-pharmacodynamic modeling in phase II of drug development. A comparative study with young and old volunteers with benzdiazepine as an example. (German) ''Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie''. 1999 Oct;34(10):634-7. PMID 10548960</ref>
'''Ro48-8684''' is a water-soluble [[benzodiazepine]] derivative developed by [[Hoffman-LaRoche]] in the 1990s, which was designed along with [[Ro48-6791]] as an improved replacement for [[midazolam]], but ultimately proved to have little advantages over the parent drug and has not been introduced into clinical practice.<ref>{{cite journal | vauthors = van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, Heizmann P, Zell M, Cohen AF, Dingemanse J | display-authors = 6 | title = Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects | journal = British Journal of Clinical Pharmacology | volume = 44 | issue = 5 | pages = 487–93 | date = November 1997 | pmid = 9384466 | pmc = 2042863 | doi = 10.1046/j.1365-2125.1997.t01-1-00613.x }}</ref><ref>{{cite journal | vauthors = Albrecht S, Hering W, Ihmsen H, Schwilden H, Schüttler J | title = [Pharmacokinetic-pharmacodynamic modeling in phase II of drug development. A comparative study with young and old volunteers with benzdiazepine as an example] | journal = Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie | volume = 34 | issue = 10 | pages = 634–7 | date = October 1999 | pmid = 10548960 | doi = 10.1055/s-1999-213 }}</ref>


== See also ==


==See also==
*[[Benzodiazepine]]
*[[Benzodiazepine]]


==References==
== References ==
{{reflist}}
{{reflist}}


{{Benzodiazepines}}
{{Benzodiazepines}}
{{GABAAR PAMs}}


[[Category:Benzodiazepines]]
[[Category:Abandoned drugs]]
[[Category:Oxazoles]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Drugs developed by Hoffmann-La Roche]]
[[Category:Imidazobenzodiazepines]]
[[Category:Imidazobenzodiazepines]]
[[Category:Lactams]]
[[Category:Lactams]]
[[Category:Organofluorides]]
[[Category:Fluoroarenes]]
[[Category:Hoffmann-La Roche]]
[[Category:Oxazoles]]